{"url_path":"/sec/mist/8-k/2026-06-15/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1408443/0001104659-26-074025-index.html","accession_number":"0001104659-26-074025","cik":"0001408443","ticker":"MIST","issuer_name":"Milestone Pharmaceuticals Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1408443/0001104659-26-074025-index.html","primary_entity_key":"0001408443","primary_entity_name":"Milestone Pharmaceuticals Inc."},"word_count":164,"has_tables":true,"body_markdown":"**Item 5.02.**\n**Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.**\n\n \n\nAt the 2026 annual meeting\nof shareholders held on June 10, 2026 (the “**Annual Meeting**”), the shareholders of Milestone Pharmaceuticals Inc.\n(the “**Company**”) approved an amendment to the Company’s 2019 Equity Incentive Plan, as amended (the “**2019\nEIP**”), to, among other things, increase the number of ordinary shares authorized for issuance by 6,800,000 shares.\n\n \n\nA more detailed summary of\nthe material features of the 2019 EIP, as amended, including the terms of equity grants thereunder, is set forth in the Company’s\n[definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 30, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/1408443/000110465926052880/tm2616218d1_def14a.htm) (the\n“**2026 Proxy Statement**”). That summary and the foregoing description is qualified in its entirety by reference to the\ntext of the 2019 EIP, as amended, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated\nherein by reference."}